All cancers are caused by somatic mutations; however, understanding of the biological
processes generating these mutations is limited. The catalogue of somatic mutations from a …

Fibroblasts often constitute the majority of the stromal cells within a breast carcinoma, yet
the functional contributions of these cells to tumorigenesis are poorly understood. Using a …

Mesenchymal stem cells have been recently described to localize to breast carcinomas,
where they integrate into the tumour-associated stroma. However, the involvement of …

We analysed whole-genome sequences of 560 breast cancers to advance understanding of
the driver mutations conferring clonal advantage and the mutational processes generating …

All cancers carry somatic mutations. The patterns of mutation in cancer genomes reflect the
DNA damage and repair processes to which cancer cells and their precursors have been …

All cancers carry somatic mutations in their genomes. A subset, known as driver mutations,
confer clonal selective advantage on cancer cells and are causally implicated in oncogenesis …

Cells with distinct phenotypes including stem-cell-like properties have been proposed to exist
in normal human mammary epithelium and breast carcinomas, but their detailed molecular …

Cancer evolves dynamically as clonal expansions supersede one another driven by shifting
selective pressures, mutational processes, and disrupted cancer genes. These processes …

Breast carcinoma is the leading cause of cancer-related mortality in women worldwide, with
an estimated 1.38 million new cases and 458,000 deaths in 2008 alone 1 . This malignancy …

Purpose Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment.
As a DNA cross-linking agent, cisplatin may be effective treatment for hereditary BRCA1-…